Morganella morganii
From IDWiki
Morganella morganii
Background
Microbiology
- Gram-negative bacillus
Clinical Manifestations
- 30% are polymicrobial12
- Sources include urinary tract, hepatobiliary tract, skin and soft tissue (including post-operative infection), and bacteremia without focus132
- Occasional cases of CLABSI and respiratory infection32
Management
- Intrinsically resistant to ampicillin, amoxicillin-clavulanic acid, first-generation cephalosporins, tigecycline (but not tetracyclines), nitrofurantoin, colistin
References
- a b T.-Y. Lin, M.-C. Chan, Y.-S. Yang, Y. Lee, K.-M. Yeh, J.-C. Lin, F.-Y. Chang. Clinical manifestations and prognostic factors of Morganella morganii bacteremia. European Journal of Clinical Microbiology & Infectious Diseases. 2014;34(2):231-236. doi:10.1007/s10096-014-2222-8.
- a b c Kevin B. Laupland, David L. Paterson, Felicity Edwards, Adam G. Stewart, Patrick N. A. Harris. Krisztina M. Papp-Wallace. Morganella morganii, an Emerging Cause of Bloodstream Infections. Microbiology Spectrum. 2022;10(3). doi:10.1128/spectrum.00569-22.
- a b David Erlanger, Marc Victor Assous, Yonit Wiener-Well, Amos Moshe Yinnon, Eli Ben-Chetrit. Clinical manifestations, risk factors and prognosis of patients with Morganella morganii sepsis. Journal of Microbiology, Immunology and Infection. 2019;52(3):443-448. doi:10.1016/j.jmii.2017.08.010.
